Breaking News

Horizon, Hisun in Cell Line Pact

Will use Horizon’s GS double knock-out cell line for antibody manufacturing

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Horizon Discovery has entered into an agreement with Hisun Pharmaceuticals to optimize its newly engineered CHO bioproduction cell line for commercial use. Hisun will use Horizon’s glutamine synthetase (GS) double knock-out cell line for use in therapeutic antibody manufacturing. Financial terms were not disclosed.   Horizon engineered the CHO cell line using its GENESIS gene editing technology. According to the company, the precision with GENESIS results in an optimal final genotype, with compl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters